The oral GLP‑1 landscape is shifting: Novo Nordisk rolled out an oral form of its GLP‑1 weight‑loss drug and Eli Lilly’s oral candidate orforglipron nears approval, marking a transition from injectable-only formulations. At the same time, employers are emerging as a new payer route—Eli Lilly and others are piloting employer‑facing programs to broaden employee access outside traditional insurer channels. These parallel moves—new oral formulations and employer programs—signal diversification of access and delivery models for obesity medicines. Payers, providers, and employers will need to reconcile coverage, cost, and clinical guidelines as oral agents and alternative payment mechanisms scale.